IceCure's Promising 5-Year Study Results for Kidney Cancer Cryoablation Show High Recurrence-Free Rates

IceCure Reports Positive 5-Year Results from ICESECRET Kidney Cancer Study

IceCure Medical Ltd., a leader in cryoablation technology, recently announced encouraging findings from its ICESECRET study, which evaluates the efficacy of its ProSense® system in treating small renal masses (SRMs) in kidney cancer patients. The results demonstrate an impressive overall recurrence-free rate of 83.9% following a median follow-up of four years, with even higher success seen in patients with tumors measuring less than 3 cm. In this subgroup, a remarkable 89.4% of patients remained recurrence-free.

As kidney cancer cases continue to rise globally, with projections estimating 400,000 new diagnoses per year, the need for effective treatments is paramount. The ICESECRET study involved 114 participants, with 112 evaluated at the follow-up mark, showcasing the safety and effectiveness of the ProSense® cryoablation system. Notably, 12 patients required a second cryoablation procedure, underscoring the system’s role as a viable alternative to more invasive surgical interventions.

Detailed Findings

The ICESECRET study was conducted in two prominent medical centers in Israel: Bnai Zion Medical Center and Shamir Medical Center. The trial’s principal investigator, Prof. Halahmi Sarel, indicated that the minimally invasive nature of cryoablation poses a significant advantage, particularly for elderly individuals or those bearing comorbidities who may not be ideal candidates for traditional surgical options.

Data collection during the study involved regular follow-up visits, including CT imaging assessments at six weeks, six months, one year, and annually for up to five years post-procedure. This meticulous approach has provided robust evidence supporting the use of the ProSense® system as part of a comprehensive treatment strategy for kidney cancer patients.

Implications for the Future

The study’s findings are set to be showcased at the upcoming European Conference on Interventional Oncology (ECIO) scheduled for April 26-30, 2026, in Basel, Switzerland. IceCure’s CEO, Eyal Shamir, expressed optimism surrounding these results, asserting that they could catalyze broader acceptance of ProSense® in markets where it's already approved, such as the United States and Europe. This adoption trend aligns with a growing preference in the healthcare landscape for less invasive procedures with lasting outcomes.

The potential of ProSense® extends beyond just kidney cancer treatment. It has also gained FDA marketing authorization for low-risk breast cancer therapy, highlighting its versatility in addressing various tumors. By capitalizing on liquid nitrogen technology, ProSense® offers a unique mechanism that effectively eliminates tumors across multiple organ systems while minimizing recovery times and complications.

Conclusion

With the ICESECRET study reinforcing the effectiveness of IceCure’s cryoablation technology, the medical community is poised to reconsider how kidney tumors are managed. As the incidence of kidney cancer increases globally, innovations like ProSense® may hold the key to transforming the standard of care. IceCure Medical continues to pioneer pathways in the treatment of cancer, reflecting a steadfast commitment to enhancing patient outcomes through advanced technology.